Morning Overview on MSN

Programmable CRISPR cuts stem cell timing from months to weeks

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...
Investor's Business Daily on MSN

Stocks to watch: CRISPR Therapeutics sees relative strength rating rise to 82

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Standard-Journal

New Research Highlights Syntax Bio’s Platform for Simple Yet Powerful Programming of Human Stem Cells

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Programmable CRISPR platform can reduce stem cell differentiation from months to weeks

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...